{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-028103","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.758455+00:00","generated_at":"2026-05-15T11:48:02.210886+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"confidence":"high","headline":"Outlook Therapeutics raises $17M via Atlas note to partially repay Avondale debt; going concern warning","bullets":["Issued $18.36M unsecured note (net $17M after OID) to Atlas Sciences; proceeds used to repay $17M of $33.1M Avondale Note.","Remaining Avondale Note balance of ~$10.8M; maturity extended to Dec 31, 2026 via amendment.","Atlas note: interest prime+3% (floor 9.5%), matures 15 months from March 16, 2026; quarterly redemption up to $3M; 7.5% exit fee.","Supplemental risk factors state substantial doubt about going concern; cash insufficient for next 12 months.","FDA issued third Complete Response Letter for ONS-5010 in Dec 2025; Type A meeting held March 2026 with no clear path."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-028103","json":"https://secwatch.observer/filing/0001104659-26-028103.json","markdown":"https://secwatch.observer/filing/0001104659-26-028103.md","text":"https://secwatch.observer/filing/0001104659-26-028103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/0001104659-26-028103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:48:02.210886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}